FLT3 mutation acute myeloid leukemia
Conditions
Interventions
experimental group:Bortezomib, homoharringtonine and Cytarabine combined chemotherapy (BHA) was used to induce remission chemotherapy, specifically Bortezomib 1.3mg/m2 d1,3,5 injection
Homoharringtonine 4mg/m2, d 1-5, intravenous drip once a day
Cytarabine 0.5g/m2, d 1-5, intravenous drip once a day.
Sponsors
The Second Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.AML (non-APL) was clearly diagnosed according to WHO criteria; 2.The disease state is relapsed or refractory; 3.FLT3 mutations were found, including FLT3-ITD and FLT3-TKD mutations; 4.Aged 18 to 65 years; 5.ECOG physical condition score was <= 3; 6.No serious complications, such as liver failure, renal failure, heart failure; 7.Must be able to understand the protocol, follow medical instructions and sign informed consent.
Exclusion criteria
Exclusion criteria: Patients with any of the following criteria were not eligible for this study: 1.Who is receiving either a chemotherapy regimen or a targeted drug; 2.Major surgery (excluding diagnostic surgery) performed within the past 4 weeks; 3.Evidence of central nervous system disease; 4.Active infectious diseases, such as HBV, HCV, tuberculosis; 5.Serious diseases that may limit patients' participation in the trial (such as progressive infection, uncontrolled diabetes, severe cardiac insufficiency or myocardial infarction, liver and kidney dysfunction, etc); 6.Participating in other clinical trials or participating in clinical trials of other drugs within 3 months; 7.Women of childbearing age must have a negative pregnancy test and agree to use effective contraception during treatment and within a year thereafter; 8.There are allergies or contraindications to any of the drugs involved in the protocol; 9.Unable to understand the experimental protocol, follow the doctor's advice, or refuse to sign the informed consent; 10.The researchers say it is not appropriate for patients who are treated with this regimen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug safety; | — |
Countries
China
Contacts
Public ContactJinsong Yan
Second Hospital of Dalian Medical University
Outcome results
None listed